A Research Study on How NNC0487-0111, a New Medicine, Works in Chinese Participants When Injected Under the Skin.

What Was Tested

The trial (phase 1) is built around Amycretin.

The study is testing a new medicine (NNC0487-0111) for weight control in Chinese people with BMI between 24 kilogram per meter square (kg/m2) and 34.9 kg/m2.

Participants will either get the study medicine or placebo (a "dummy medicine" similar to the study medicine but without active ingredients) and which treatment they get is decided by chance.

It had three arms (groups): Cohort A1 (experimental), Cohort A2 (experimental) and Cohort A3 (experimental).

The registry classes the interventions as drug.

Who Took Part

36 actual participants took part.

It was open to men only aged from 18 years up to 55 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. Male Chinese participants, age 18-55 years (both inclusive) at the time of signing the informed consent. Considered eligible based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.

The full record lists 4 inclusion and 9 exclusion criteria; among the exclusions: any condition, unwillingness or inability which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol; hba1c ≥ 6.5 percent (%) \[48 milimol per mole (mmol/mol)\] at screening; any laboratory safety parameters at screening outside the below laboratory ranges:.

How the Study Was Run

It was run as a randomized, sequential and double-blind study.

The participants were allocated by chance, so the Amycretin group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Amycretin.

Those kept unaware of assignments: participant and investigator.

It started in 2025-08-11 with completion listed for 2025-12-20.

It ran at 1 site in China.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Number of treatment emergent adverse events (TEAEs) (time frame: From NNC0487-0111 administration (Day 1) to completion of the end of study visit (Day 23)).

It also tracked 6 secondary outcomes, for example Relative change in body weight and Change in fasting plasma glucose.

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Amycretin in 36 people.

Its size is small, so on its own it can only give an early look.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Amycretin compound page, all human trials.